Kaiserman Igor, Rabina Gilad, Mimouni Michael, Sadi Optom Naava B, Duvdevan Nitsan, Levartovsky Shmuel, Ben David David
Department of Ophthalmology, Barzilai University Medical Center , Ashkelon, Israel.
Faculty of Health Sciences, Ben-Gurion University of the Negev , Be'er Sheva, Israel.
Curr Eye Res. 2021 Feb;46(2):195-201. doi: 10.1080/02713683.2020.1789663. Epub 2020 Aug 25.
To determine the clinical benefits of Meibomian gland expression therapy for the treatment of dry-eye disease caused by Meibomian gland dysfunction (MGD).
In a prospective randomized controlled double-masked trial, 87 eyes of 44 patients with MGD and dry-eye symptoms were enrolled. Patients were randomly assigned into two groups; a study group that received therapeutic Meibomian gland expression once every month, and a control group that received sham treatment. All patients received treatment with artificial tears.
One week after the first treatment, the Ocular Surface Disease Index (OSDI) score improved significantly in the study group (mean change -18.5 ± 21.2, = .01) but not in the control group (-3.8 ± 15.8, = .16); after 1 month, both groups improved significantly (-20.5 ± 19 = .001 in the study group and -6.5 ± 11, = .016 in the control group). The improvement continued at 2 months in the study group (-28.4 ± 26.1, < .0001) and in the control group (-9.6 ± 9.9, = .007). The blepharitis questionnaire score improved in the study group compared to controls after 1 week (-9.95 ± 12.52 versus -1.77 ± 9.1, = .03) 1 month (-11.5 ± 10.9 versus -1.1 ± 9.4, = .02) and 2 months (-16.5 ± 8.0 versus -8.8 ± 11.7, = .02). Burning sensation was significantly reduced only in the study group. Mean change after 2-month treatment was -2.00 ± 1.2583 ( < .0001) vs -0.67 ± 1.44 ( = .08). The trend was similar in Eyelid scales. Conjunctival hyperemia improved only in the study group 1 week after the treatment (-0.12 ± 0.32 = .03).
Therapeutic Meibomian gland expression improves dry-eye symptoms in subjects with MGD, compared to conventional treatment with artificial tears.
确定睑板腺挤压疗法对治疗睑板腺功能障碍（MGD）所致干眼症的临床疗效。
在一项前瞻性随机对照双盲试验中，纳入了44例患有MGD且有干眼症状的患者的87只眼睛。患者被随机分为两组；研究组每月接受一次治疗性睑板腺挤压，对照组接受假治疗。所有患者均接受人工泪液治疗。
首次治疗后1周，研究组的眼表疾病指数（OSDI）评分显著改善（平均变化-18.5±21.2，P =.01），而对照组未改善（-3.8±15.8，P =.16）；1个月后，两组均有显著改善（研究组为-20.5±19，P =.001；对照组为-6.5±11，P =.016）。研究组在2个月时改善持续（-28.4±26.1，P <.0001），对照组也有改善（-9.6±9.9，P =.007）。1周后（-9.95±12.52对-1.77±9.1，P =.03）、1个月后（-11.5±10.9对-1.1±9.4，P =.02）和2个月后（-16.5±8.0对-8.8±11.7，P =.02），研究组的睑缘炎问卷评分与对照组相比有所改善。仅研究组的烧灼感显著降低。2个月治疗后的平均变化为-2.00±1.2583（P <.0001），而对照组为-0.67±1.44（P =.08）。睑缘鳞屑的趋势相似。治疗1周后仅研究组的结膜充血有所改善（-0.12±0.32，P =.03）。
与人工泪液的传统治疗相比，治疗性睑板腺挤压可改善MGD患者的干眼症状。
